

Author's Accepted Manuscript

Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial

D. Robert Siemens , Laurence Klotz , Axel Heidenreich , Simon Chowdhury , Arnauld Villers , Benoit Baron , Steve van Os , Nahla Hasabou , Fong Wang , Ping Lin , Neal D. Shore



PII: S0022-5347(17)77377-6
DOI: [10.1016/j.juro.2017.08.080](https://doi.org/10.1016/j.juro.2017.08.080)
Reference: JURO 14936

To appear in: *The Journal of Urology*
Accepted Date: 13 August 2017

Please cite this article as: Siemens DR, Klotz L, Heidenreich A, Chowdhury S, Villers A, Baron B, van Os S, Hasabou N, Wang F, Lin P, Shore ND, Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial, *The Journal of Urology*® (2017), doi: 10.1016/j.juro.2017.08.080.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial

D. Robert Siemens,* Laurence Klotz, Axel Heidenreich, Simon Chowdhury, Arnauld Villers, Benoit Baron, Steve van Os, Nahla Hasabou, Fong Wang, Ping Lin and Neal D. Shore

From the Centre for Applied Urological Research, Queen's University, Kingston, Ontario, Canada (DRS), Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (LK), Department of Urology, University of Cologne, Cologne, Germany (AH), Guy's, King's and St Thomas' Hospitals, London, UK (SC), Department of Urology, Lille University, Lille, France (AV), Astellas Pharma, Inc., Leiden, the Netherlands (BB, SvO), Astellas Pharma, Inc., Northbrook, IL, USA (NH), Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, San Francisco, CA, USA (FW, PL) and the Carolina Urologic Research Center, Myrtle Beach, SC, USA (NDS)

*** Correspondence:** Victory 4, Kingston General Hospital, 76 Stuart St., Kingston, Ontario K7L2V7, Canada (telephone: 613-548-2411; FAX: 613-545-1970; e-mail: siemensr@KGH.KARI.NET)

Other author emails: laurence.klotz@sunnybrook.ca; axel.heidenreich@uk-koeln.de; simon.chowdhury@gstt.nhs.uk; arnauld.villers@wanadoo.fr; benoit.baron@astellas.com; nahla.hasabou@astellas.com; steve.vanos@astellas.com; fong.wang@medivation.com; ping.lin@medivation.com; nshore@gsuro.com

Running head: Enzalutamide vs bicalutamide in older mCRPC patients

Download English Version:

<https://daneshyari.com/en/article/8771834>

Download Persian Version:

<https://daneshyari.com/article/8771834>

[Daneshyari.com](https://daneshyari.com)